Singapore Clinical Trial: Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas

Singapore, March 19 -- The Health Sciences Authority received information related to the study titled 'Antigen Targeted T cell therapy for Relapsed/Refractory B cell Lymphomas'. The following are the ... Read More

Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, March 19 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More

Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, March 19 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and... Read More

Singapore Clinical Trial: A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in hypertensive patients.

Singapore, March 19 -- The Health Sciences Authority received information related to the study titled 'A multicenter open-label extension study to evaluate long-term safety and efficacy of QCZ484 in h... Read More

Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, March 19 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asci... Read More

Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, March 19 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib wit... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, March 19 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy... Read More

RSS must boost social media activism amid expanding work: Mohan Bhagwat

Nagpur, March 19 -- Emphasising the growing influence of digital platforms, Rashtriya Swayamsevak Sangh(RSS) chief Mohan Bhagwat on Thursday said that the Sangh needs to enhance its presence and activ... Read More

Bihar to Soon Join the League of Developed States: Nitish

Munger, March 19 -- Chief minister Nitish Kumar said on Thursday that Bihar was on the way to development and would soon join the league of developed states in the country. Addressing a public intera... Read More

Delhi HC orders Tamil media outlet to take down 'defamatory' content against Sadhguru's Isha Foundation

New Delhi, March 19 -- The Delhi High Court on Thursday directed Tamil news magazine Nakkheeran Publications to delete and take down defamatory content against Jaggi Vasudev's Isha Foundation. Sadhgu... Read More

• ««
• «
• 116748
• 116749
• 116750
• 116751
• 116752
• 116753
• 116754
• 116755
• 116756
• 116757
• »
• »»